Sage Therapeutics soars on its depression drug

Sage Therapeutics reports ‘positive’ results from Phase 2 trial of SAGE-217

Sage Therapeutics announces results from Sage-217

Sage Therapeutics (SAGE) announced positive top-line results from the Phase 2, double-blind, placebo-controlled clinical trial of SAGE-217 in the treatment of 89 adult patients with moderate to severe major depressive disorder.

In the trial, treatment for 14 days with SAGE-217 was associated with a statistically significant mean reduction in the Hamilton Rating Scale for Depression 17-Item total score from baseline to Day 15 (the time of the primary endpoint) of 17.6 points for SAGE-217, compared to 10.7 for placebo (less than 0.0001).

Statistically significant improvements were observed in the HAM-D compared to placebo by the morning following the first dose through Week 4 and the effects of SAGE-217 remained numerically greater than placebo through the end of follow-up at Week 6. At Day 15, 64 percent of patients who received SAGE-217 achieved remission, defined as a score of 7 or less on the HAM-D scale, compared with 23 percent of patients who received placebo (p=0.0005).

Other secondary endpoints were all similarly highly significant at Day 15 (less than or equal to 0.002). SAGE-217 was generally well-tolerated with no serious or severe adverse events; the most common adverse events in the SAGE-217 group were headache, dizziness, nausea, and somnolence.

A low rate of discontinuations due to AEs was reported; overall reports of AEs were similar between drug (53%) and placebo (46%), with a safety profile consistent with that seen in earlier trials. SAGE-217 was granted Fast Track Designation by the U.S. FDA in May 2017.

PRICE ACTION

SAGE has a 52-weeks trading range of $44.55 – $100.50. Shares closed at $91.90. It last traded at $145 in pre-market trading.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Leave a Reply

Your email address will not be published. Required fields are marked *